ruboxistaurin has been researched along with Diabetes Mellitus, Adult-Onset in 20 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 13 (65.00) | 29.6817 |
| 2010's | 6 (30.00) | 24.3611 |
| 2020's | 1 (5.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lu, M; Ran, C; Wang, H; Xu, Y; Zhang, J; Zhao, F | 1 |
| Alicic, RZ; Tuttle, KR | 1 |
| Aiello, LP; Danis, RP; Davis, MD; Girach, A; Jimenez, MC; Milton, RC; Sheetz, MJ; Vignati, L; Zhi, X | 1 |
| Amrutia, S; Comiskey, L; Iqbal, N; Mehta, NN; Mohler, ER; Price, K; Reilly, MP; Sheetz, M | 1 |
| Beckman, JA; Creager, MA; Goldfine, AB; Goldin, A; Kim, S; Prsic, A | 1 |
| Majji, AB; Sahu, AK | 1 |
| Ebadi, SA; Golbidi, S; Laher, I | 1 |
| Bean, JS; Kassab, GS; Lu, X; Rekhter, MD | 1 |
| Boyd, A; Casselini, C; Vinik, A; Vinik, E | 1 |
| Lagrèze, WA | 1 |
| Aiello, LP; Klemp, K; Larsen, M; Lund-Andersen, H; Sander, B; Strøm, C | 1 |
| Anderson, PW; Bakris, GL; Hu, K; McGill, JB; Toto, RD; Tuttle, KR | 1 |
| He, Z; King, GL | 1 |
| Vinik, A | 1 |
| Aiello, LP; Arora, V; Bursell, SE; Clermont, A; Davis, MD; Sheetz, MJ | 1 |
| Lebovitz, H | 1 |
| Anderson, PW; Bakris, GL; Gilbert, RE; Haney, DJ; Kelly, DJ; Kim, SA; McGill, JB; Toto, RD; Tuttle, KR | 1 |
| Barlow, PM; Bastyr, EJ; Casellini, CM; Casey, M; Pittenger, G; Rice, AL; Simmons, K; Vinik, AI; Wolka, AM | 1 |
| Haneda, M; Isshiki, K; Kashiwagi, A; Kikkawa, R; King, GL; Koya, D; Maeda, S; Nakagawa, H; Sato, H; Sugimoto, T; Ways, DK; Yasuda, H | 1 |
5 review(s) available for ruboxistaurin and Diabetes Mellitus, Adult-Onset
| Article | Year |
|---|---|
Novel therapies for diabetic kidney disease.
Topics: Acetylcysteine; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antihypertensive Agents; Antioxidants; Bosentan; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Endothelins; Enzyme Inhibitors; Glycation End Products, Advanced; Humans; Hypoglycemic Agents; Indoles; Janus Kinases; Maleimides; Polyamines; Protein Kinase C; Pyridones; Pyridoxamine; Sevelamer; Sulfonamides | 2014 |
Antioxidants in the treatment of diabetes.
Topics: Antioxidants; Ascorbic Acid; Carnitine; Clinical Trials as Topic; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Type 2; Female; Humans; Indoles; Male; Maleimides; Oxidative Stress; Thioctic Acid; Treatment Outcome; Ubiquinone; Vitamins | 2011 |
[New prospects in the treatment of diabetic retinopathy. Current situation and pharmacological developments].
Topics: Adult; Aged; Clinical Trials as Topic; Clinical Trials, Phase I as Topic; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Retinopathy; Enzyme Inhibitors; Female; Humans; Indoles; Integrins; Laser Coagulation; Male; Maleimides; Mass Screening; Matrix Metalloproteinase Inhibitors; Middle Aged; Pregnancy; Pregnancy in Diabetics; Protein Kinase C; Risk Factors; Vascular Endothelial Growth Factor A | 2003 |
The protein kinase C-beta inhibitor, ruboxistaurin, for the treatment of diabetic microvascular complications.
Topics: Animals; Diabetes Complications; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Indoles; Maleimides; Microcirculation; Protein Kinase C; Protein Kinase C beta | 2005 |
Diabetes: assessing the pipeline.
Topics: Adamantane; Alkanesulfonates; Amyloid; Diabetes Mellitus, Type 2; Enzyme Inhibitors; Exenatide; Glycine; Humans; Hypoglycemic Agents; Indoles; Islet Amyloid Polypeptide; Maleimides; Nitriles; Oxazoles; Peptides; Phenylpropionates; Piperidines; PPAR alpha; PPAR gamma; Protein Kinase C; Pyrazoles; Pyrrolidines; Receptor, Cannabinoid, CB1; Receptors, Glucagon; Rimonabant; Venoms; Vildagliptin | 2006 |
10 trial(s) available for ruboxistaurin and Diabetes Mellitus, Adult-Onset
| Article | Year |
|---|---|
Effect of ruboxistaurin on the visual acuity decline associated with long-standing diabetic macular edema.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Cross-Sectional Studies; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Retinopathy; Double-Blind Method; Enzyme Inhibitors; Female; Humans; Indoles; Macular Edema; Male; Maleimides; Middle Aged; Protein Kinase C; Severity of Illness Index; Time Factors; Vision Disorders; Vision Tests; Visual Acuity | 2009 |
Selective PKC beta inhibition with ruboxistaurin and endothelial function in type-2 diabetes mellitus.
Topics: Brachial Artery; Diabetes Mellitus, Type 2; Double-Blind Method; Endothelium, Vascular; Enzyme Inhibitors; Female; Humans; Indoles; Male; Maleimides; Middle Aged; Oxidative Stress; Protein Kinase C; Ultrasonography; Vasodilation | 2009 |
Inhibition of protein kinase Cbeta does not improve endothelial function in type 2 diabetes.
Topics: Adult; Aged; Analysis of Variance; Cross-Over Studies; Diabetes Mellitus, Type 2; Double-Blind Method; Endothelium, Vascular; Enzyme Inhibitors; Female; Forearm; Humans; Indoles; Male; Maleimides; Middle Aged; Oxidative Stress; Protein Kinase C; Protein Kinase C beta; Vasodilation | 2010 |
Quality of life and objective measures of diabetic neuropathy in a prospective placebo-controlled trial of ruboxistaurin and topiramate.
Topics: Adult; Aged; Anticonvulsants; Diabetes Complications; Diabetes Mellitus, Type 2; Diabetic Neuropathies; Female; Fructose; Humans; Indoles; Male; Maleimides; Middle Aged; Placebos; Protein Kinase Inhibitors; Quality of Life; Research Design; Surveys and Questionnaires; Topiramate | 2011 |
Effect of ruboxistaurin on blood-retinal barrier permeability in relation to severity of leakage in diabetic macular edema.
Topics: Administration, Oral; Adult; Aged; Blood Pressure; Blood-Retinal Barrier; Capillary Permeability; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Retinopathy; Double-Blind Method; Enzyme Inhibitors; Female; Glycated Hemoglobin; Humans; Indoles; Macular Edema; Male; Maleimides; Middle Aged; Protein Kinase C; Retina; Retinal Vessels | 2005 |
The effect of ruboxistaurin on nephropathy in type 2 diabetes.
Topics: Aged; Albuminuria; Black or African American; Creatinine; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Double-Blind Method; Enzyme Inhibitors; Female; Glomerular Filtration Rate; Humans; Indoles; Male; Maleimides; Middle Aged; Pilot Projects; Time Factors; United States; White People | 2005 |
Inhibition of PKC beta by oral administration of ruboxistaurin is well tolerated and ameliorates diabetes-induced retinal hemodynamic abnormalities in patients.
Topics: Administration, Oral; Adolescent; Adult; Aged; Blood Flow Velocity; Blood-Retinal Barrier; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Retinopathy; Double-Blind Method; Enzyme Inhibitors; Female; Hemodynamics; Humans; Indoles; Male; Maleimides; Middle Aged; Protein Kinase C; Protein Kinase C beta; Retinal Vessels | 2006 |
Effect of ruboxistaurin on urinary transforming growth factor-beta in patients with diabetic nephropathy and type 2 diabetes.
Topics: Adult; Creatinine; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Double-Blind Method; Enzyme Inhibitors; Humans; Indoles; Maleimides; Middle Aged; Placebos; Protein Kinase C; Protein Kinase C beta; Transforming Growth Factor beta | 2007 |
Effect of ruboxistaurin in patients with diabetic macular edema: thirty-month results of the randomized PKC-DMES clinical trial.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Retinopathy; Disease Progression; Double-Blind Method; Enzyme Inhibitors; Female; Humans; Indoles; Laser Coagulation; Macular Edema; Male; Maleimides; Middle Aged; Prospective Studies; Protein Kinase C; Protein Kinase C beta; Treatment Outcome; Visual Acuity | 2007 |
A 6-month, randomized, double-masked, placebo-controlled study evaluating the effects of the protein kinase C-beta inhibitor ruboxistaurin on skin microvascular blood flow and other measures of diabetic peripheral neuropathy.
Topics: Aged; Blood Flow Velocity; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Neuropathies; Enzyme Inhibitors; Female; Humans; Indoles; Male; Maleimides; Microcirculation; Middle Aged; Placebos; Protein Kinase C; Protein Kinase C beta; Racial Groups; Regional Blood Flow; Skin | 2007 |
5 other study(ies) available for ruboxistaurin and Diabetes Mellitus, Adult-Onset
| Article | Year |
|---|---|
Ginsenoside Rg1 attenuates diabetic vascular endothelial dysfunction by inhibiting the calpain-1/ROS/PKC-β axis.
Topics: Animals; Calpain; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Endothelial Cells; Endothelium, Vascular; Humans; Male; Mice; Mice, Inbred C57BL; Oxidative Stress; Reactive Oxygen Species; Vascular Diseases | 2023 |
Effect of ruboxistaurin on the visual acuity decline associated with long-standing diabetic macular edema.
Topics: Administration, Oral; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Retinopathy; Enzyme Inhibitors; Humans; Indoles; Macular Edema; Maleimides; Protein Kinase C; Severity of Illness Index; Vision Disorders; Vision Tests; Visual Acuity | 2010 |
Protein kinase C inhibition ameliorates functional endothelial insulin resistance and vascular smooth muscle cell hypersensitivity to insulin in diabetic hypertensive rats.
Topics: Analysis of Variance; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Blood Glucose; Blood Pressure; Captopril; Diabetes Mellitus, Type 2; Disease Models, Animal; Dose-Response Relationship, Drug; Endothelial Cells; Femoral Artery; Hypertension; Indoles; Insulin; Insulin Resistance; Male; Maleimides; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; Myography; Protein Deficiency; Protein Kinase C; Protein Kinase Inhibitors; Rats; Rats, Sprague-Dawley; Sodium Chloride, Dietary; Telemetry; Time Factors; Vasoconstriction; Vasoconstrictor Agents; Vasodilation; Vasodilator Agents | 2011 |
Can protein kinase C beta-selective inhibitor, ruboxistaurin, stop vascular complications in diabetic patients?
Topics: Diabetes Mellitus, Type 2; Diabetic Angiopathies; Endothelium, Vascular; Enzyme Inhibitors; Humans; Indoles; Maleimides; Protein Kinase C; Protein Kinase C beta; Treatment Outcome | 2005 |
Amelioration of accelerated diabetic mesangial expansion by treatment with a PKC beta inhibitor in diabetic db/db mice, a rodent model for type 2 diabetes.
Topics: Albuminuria; Animals; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Enzyme Inhibitors; Gene Expression Regulation; Glomerular Mesangium; Indoles; Isoenzymes; Kidney Glomerulus; Male; Maleimides; Mice; Mice, Mutant Strains; Protein Kinase C; Protein Kinase C beta; Rats; Transforming Growth Factor beta | 2000 |